Other · developed by Genmab
GEN1119 is an investigational agent studied in solid tumours.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07695831 | Phase 1 | Solid Tumours | Recruiting | GMAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumours
Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.
See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GMAB catalysts and pipeline →